Descrizione del progetto
Un nuovo vaccino per salvaguardare la salute e la produttività del bestiame bovino
La vaccinazione rappresenta la strategia più efficiente per proteggere il bestiame da varie malattie, riducendo al minimo l’impiego di antibiotici. La diarrea virale bovina (BVD) è una malattia endemica che colpisce i bovini provocata dal virus BVD (BVDV). Non esistono al momento programmi per l’eradicazione o il controllo di questa patologia, che eviterebbero di dover ricorrere ai vaccini. Il progetto BoVLP-BVD, finanziato dall’UE, ha sviluppato un nuovo vaccino contro il BVDV basato su una tecnologia brevettata che si avvale di una particella virus-simile. Gli scienziati effettueranno le attività necessarie alla produzione su scala commerciale e una valutazione in vivo dell’efficacia e della sicurezza del vaccino. Dato che il BVDV influenza in modo significativo la produttività e la riproduzione delle mandrie, comportando ingenti costi a livello economico, il vaccino BoVLP-BVD contribuirà alla prevenzione della malattia causata da tale virus.
Obiettivo
In a general context of environmental, social and legal pressure to reduce the use of antibiotics to fight diseases in livestock animals, cost-effective vaccination becomes the focus of most of the industry, regulatory and agro-food public bodies. Development of new vaccines to prevent the disease and therefore avoid the use of antibiotics or to improve suboptimal available vaccines is now an European and industry priority. Bovine viral diarrhea virus (BVDV) is an important infectious agent of cattle worldwide that affects herd productivity and reproduction. BVD has been and is an endemic disease in all countries where no systematic eradication and control programs have been established. Under these conditions, approximately 50% of the herds have or have had animals with persistent infection, and approximately 90% of the cattle have been exposed to the virus at some point during their lifetime. Infection with BVDV has a major economic impact, estimated in hundreds of euros per animal for a European hut of around 80 million animals.
Aquilón CyL, a leading biotech company, has developed new recombinant vaccine against BVDV using a Virus-Like- Particle patented technology. Aquilón has demonstrated the technical, commercial and regulatory feasibility by the SME instrument phase 1 project (nº 774994). After developing the vaccine to TRL6 stage (pre-industrial prototype with positive activity data), Aquilón will develop one vaccine to TRL8 stage, demonstrating the commercial-scale manufacturing and in-vivo safety, efficacy and DIVA attributes in the target species. This vaccine candidate will be licensed to one or more veterinarian pharmaceutical company that will complete the final field studies required for commercialisation. Our business projections, based on agreements with Development milestones and commercial royalties, show potential for a 5X investment multiplier with a 25% internal rate of return.
Campo scientifico
- natural sciencesbiological sciencesmicrobiologyvirology
- social scienceseconomics and businesseconomicsproduction economicsproductivity
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- agricultural sciencesanimal and dairy sciencedomestic animalsanimal husbandry
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEInst-2018-2020-2
Meccanismo di finanziamento
SME-2 - SME instrument phase 2Coordinatore
24000 LEON
Spagna
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.